Strategic Diagnostics' Q2 Revenues Rise 5 Percent | GenomeWeb

NEW YORK (GenomeWeb news) – Strategic Diagnostics reported after the close of the market on Thursday that its second-quarter revenues increased 5 percent, and the firm cuts its net loss around 3 percent year over year.

The Newark, Del.-based firm brought in revenues of $6.9 million for the three-month period ended June 30, compared to revenues of $6.6 million for the second quarter of 2008. The company said that its revenues were positively impacted by a 16 percent increase in life science revenues and a 45 percent increase in sales of its Genomic Antibody Technology products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.